BioSpace News Archive

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) announces that it has been approved for funding totaling approximately $40,000 to support the development of its intellectual property portfolio.

Edison Oncology Holding Corp. (“Edison Oncology”), a privately held biopharmaceutical company, today announced the presentation of positive interim data from the company’s ongoing multicenter Phase 1/2a clinical trial of Orotecan (oral irinotecan HCL, VAL-413) at the American Association of Cancer Research (AACR) annual meeting.

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that Denosumab Injection (trade name: MAIWEIJIAN, R&D code: 9MW0321) developed by its wholly-owned subsidiary T-mab has officially obtained the marketing authorization approval by National Medical Products Administration (NMPA) (Drug Approval Number: [GYZZ]S20240010).

AustinPx announced its acquisition of a 3P Innovations API in capsule filling machine, a FT4 Powder Rheometer®, and the STYL’One Nano compaction simulator.

Medigene AG presents superior recombinant T cell receptor engineered T cell functionality as well as a favorable safety profile when rTCR-T cells are armored and enhanced with the PD1-41BB costimulatory switch protein at the American Association for Cancer Research Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, USA.

Sensorion announced a €15 million offering reserved to specific categories of investors through the issuance of 24,574,694 new ordinary shares of the Company at a price per New Share of €0.63 to the benefit of existing shareholders including Redmile Group, Invus, Sofinnova Partners and a large investment management firm.

Nxera Pharma Co. Ltd – formerly known as Sosei Group or Sosei Heptares – announces it has joined the World Orphan Drug Alliance, a global alliance of commercial distributors dedicated to providing access to treatments for rare diseases and specialty medicines in complex markets around the world.

Building upon their partnership announced last year, digital health leader Dawn Health and global pharmaceutical company Novartis are proud to announce the launch of Ekiva PNH, an innovative digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria.

Clover Biopharmaceuticals, Ltd. announced positive preliminary immunogenicity and safety data in the initial young adult cohort from its Phase I trial evaluating SCB-1019 – the company’s bivalent RSV prefusion-stabilized F -Trimer subunit vaccine candidate – which is based on Clover’s Trimer-Tag vaccine technology platform.

BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced that it will hold a conference call to update shareholders on the NurOwn® program tomorrow, April 9, at 8:00 AM Eastern Time.